Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0USILO)
ADC Name
TAC-001
Synonyms
CD22 targeting TRAAC-Tallac Therapeutics; TAAC-001; TAC 001; TAC-001
   Click to Show/Hide
Organization
Tallac Therapeutics, Inc.
Drug Status
Phase 1/2
Antibody Name
Mozistobart
  Antibody Info 
Antigen Name
B-cell receptor CD22 (CD22)
  Antigen Info 
Payload Name
Differentiated TLR-9 agonist (T-CpG)
  Payload Info 
Linker Name
Undisclosed
Combination Type
Zoratolimod
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
Disease Name Phase 1 Phase 2 Phase 3 Approved
Unspecific solid tumor
1 Trials
Clinical trial identifier
NCT05399654
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05399654
PHASE1|||PHASE2
A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Undisclosed  NCT05399654
Phase 1/2
A phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Key inclusion: Histologically/cytologically confirmed solid tumors, ECOG PS 0-1, and adequate organ function
Administration Dosage
TAC-001 Single-Agent Dose-Escalation Cohorts
Related Clinical Trial
NCT Number NCT05399654  Clinical Status PHASE1|||PHASE2
Clinical Description A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Primary Endpoint
Primary objectives include determining the RP2D of TAC-001 monotherapy in advanced/metastatic solid tumors [2 years], and evaluating preliminary efficacy through ORR (CR+PR), duration of response, and clinical benefit rate per RECIST 1.1/iRECIST [2 years].
Other Endpoint
Secondary endpoints assess safety (AE/SAE/irAE incidence via CTCAE v5.0 [2 years]), pharmacokinetics (Cmax, Tmax, AUC, half-life, clearance [2 years]), and immunogenicity (ADA incidence [2 years]).
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT05399654  Clinical Status Phase 1/2
Clinical Description A phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors.
References
Ref 1 A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Ref 2 A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors, NCT05399654